Liposomes: A Promising Strategy to Treat Multidrug Resistance in Cancers

Abstract

Drug resistance has become a main concern in the cancer therapy worldwide. It can be a temporary or permanent potential of an organismto multiply even in the presence of the lethal drug concentration.Generally, multidrug resistance (MDR) is associated with the over-expression of P-glycoprotein(P-gp), resulting in amplified efflux of anticancer drug molecules from cancer cells [1]. Therefore, interrupting the P-gp efflux might be an effective strategy to resolve the MDR in cancer patients. Interestingly, smart nano-sized transporters can deliver the drug cargo at the proposed site and release the drug precisely to elicit desirable therapeutic response. Thanks to their small diameter, large surface area. Now a days, researchers have explored a smart drug delivery system known as polymer lipid hybrid nanoparticles, which are capable to combat various diseases [2,3]. Over expressed ATP-Binding Cassette (ABC) transporters is frequently associated with MDR in cancer treatments. However, no approved anti-cancer drug molecules are available for clinical use in order to reverse MDR by obstructing P-glycoprotein. However, MDR is responsible for the low intracellular drug concentrations ultimately reduce the cytotoxicity of a broad spectrum of antitumor drugs including anthracyclines (e.g. DOX), vinca alkaloids (e.g. vincristine), podophyllotoxins (e.g. etoposide) and taxanes (e.g. taxol) [4].